This text discusses non-metastatic colon cancer treatment options, including the use of capecitabine and oxaliplatin-based regimens. It recommends considering oxaliplatin-based regimens for patients under 70 with specific tumor characteristics. It also mentions the importance of monitoring and managing neurotoxicity. Additionally, it suggests adjuvant chemotherapy with fluoropyrimidines and oxaliplatin for certain stage II colon cancers, and highlights the need for DPYD genotyping in cases of abnormal DPD phenotype. The text also emphasizes the benefits of moderate physical activity for patients. Finally, it mentions a clinical trial studying the use of aspirin in colon cancer patients with PI3K mutations.